CompanyLunit, Inc.
South Korea
Lunit is a medical AI software company devoted to providing AI-powered total cancer care. Company's AI solutions help discover cancer and predict cancer treatment outcomes, achieving timely and individually-tailored cancer treatment.
Private/Public:
private
Email:[email protected]
Website:https://www.lunit.io/en/
Address:15F, 27, Teheran-ro 2-gil, Gangnam-gu, Seoul, South Korea
2013
Since
1
Country
1
Top Service Category
5
Sub-Service Categories
Product Groups
For Services/Products
Diagnostics
Diagnostic Imaging Services/Technologies
South Korea
- (23.Jun.2022) 4 Firms Agree to Form a Medical AI Alliance
- (20.Jun.2022) Lunit AI Solution for Radiology Receives Health Canada Nod for Commercial Use
- (16.Jun.2022) Lunit Seeks to List Shares on Kosdaq Market in July
- (27.May.2022) New Studies at ASCO 2022 Validate Effectiveness of Lunit AI as Diagnostic Aid in Cancer Treatment
- (28.Apr.2022) Lunit to Present 11 Abstracts at the 2022 ASCO Annual Meeting
- (27.Apr.2022) Lunit AI Solution for PD-L1 Expression Analysis Receives CE Mark
- (21.Apr.2022) Medical AI Startup Lunit Gets Preliminary Approval to Go Public on KOSDAQ
- (06.Apr.2022) New Studies at AACR 2022 Highlight Lunit SCOPE's Immune Phenotyping Capabilities
- (24.Mar.2022) Lunit to Supply AI Platform to the Middle East
- (20.Mar.2022) Lunit AI Demonstrates Accuracy in Practical Assessment of Cancer Tissue-Findings to Be Presented at USCAP 2022
- (16.Mar.2022) Breakthrough Study Validates Artificial Intelligence as a Novel Biomarker in Predicting Immunotherapy Response - Published in Journal of Clinical Oncology
- (18.Jan.2022) Baheya Foundation, Egypt's Premier Destination for Breast Cancer, Adopts Lunit AI to Enhance Early Screening
- (27.Dec.2021) Lunit Obtains MDSAP Certificate, Granted Fast-Track Regulatory Process in Major Countries
- (08.Dec.2021) Lunit Named to the 2021 CB Insights Digital Health 150 -- List of Most Innovative Digital Health Startups
- (25.Nov.2021) Medical AI Provider Lunit Raises $61M in Funding Round Led by Major Global Healthcare Investors
- (22.Nov.2021) Research Backs Clinical Efficacy of Lunit's Radiology AI Products; Abstracts to Be Presented at RSNA 2021
- (18.Nov.2021) Lunit's AI Software for Breast Cancer Detection, Lunit INSIGHT MMG, Wins FDA Clearance
- (15.Nov.2021) Lunit's AI-based Image Reading Solution Wins FDA Clearance
- (11.Nov.2021) Lunit Presents Studies at SITC 2021, Highlighting the Effectiveness of AI in Predicting Response to Immunotherapy in a Clinical Trial Setting
- (08.Nov.2021) RadLink, Singapore's Leading Imaging Center, Adapts Lunit AI to Analyze Chest X-Rays and Mammograms
- (08.Nov.2021) Lunit Scouts Healthcare Experts to Enhance Global Competitiveness
- (19.Oct.2021) Lunit, Medpacto Agree to Co-Develop AI-based Biomarkers for Novel Drugs
- (17.Sep.2021) Lunit AI Applied to Clinical Trial for Drug Development for the First Time--Findings Presented at ESMO 2021
- (06.Sep.2021) Lunit AI Receives HSA Approval, Now Commercially Available in Singapore
- (19.Aug.2021) Lunit Collaborates with Intel to Provide AI Solutions to CPU-Based Customers in Need of Effective X-Ray Diagnosis
- (12.Aug.2021) Fujifilm Introduces Its AI-powered Product for Chest X-Ray in Japan, in Collaboration With Lunit
- (12.Aug.2021) Lunit-Fujifilm's AI-based Lung Disease Diagnostic Device Wins Approval in Japan
- (29.Jul.2021) A Multi-Reader Study Finds Unnecessary CT Exams Can Be Reduced by 30% When Analyzing Chest Radiographs With AI
- (19.Jul.2021) Lunit Secures $26M Investment from Guardant Health in a Strategic Funding Round